Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $516.5 million.

  • Coherus Oncology's Liabilities and Shareholders Equity rose 228.1% to $516.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 3099.19%. This contributed to the annual value of $448.5 million for FY2024, which is 2875.95% down from last year.
  • As of Q3 2025, Coherus Oncology's Liabilities and Shareholders Equity stood at $516.5 million, which was up 228.1% from $439.5 million recorded in Q2 2025.
  • In the past 5 years, Coherus Oncology's Liabilities and Shareholders Equity ranged from a high of $763.5 million in Q1 2024 and a low of $371.1 million during Q1 2025
  • For the 5-year period, Coherus Oncology's Liabilities and Shareholders Equity averaged around $570.0 million, with its median value being $550.9 million (2022).
  • Per our database at Business Quant, Coherus Oncology's Liabilities and Shareholders Equity skyrocketed by 8973.55% in 2024 and then crashed by 5140.22% in 2025.
  • Coherus Oncology's Liabilities and Shareholders Equity (Quarter) stood at $679.3 million in 2021, then dropped by 29.22% to $480.8 million in 2022, then surged by 30.94% to $629.6 million in 2023, then decreased by 28.76% to $448.5 million in 2024, then rose by 15.16% to $516.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $516.5 million in Q3 2025, compared to $439.5 million in Q2 2025 and $371.1 million in Q1 2025.